Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.

S, Cicero; R, Bindra; G, Rembouskos; K, Spencer; KH, Nicolaides

doi:10.1002/pd.588

Public

Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.

Shared by NobleBlocks on Apr 1, 2003 • 12:00 AM UTC

Authors:

Cicero S

Bindra R

Rembouskos G

Abstract

Background Screening for trisomy 21 by a combination of maternal age, fetal nuchal translucency (NT) thickness and maternal serum free beta-hCG and pregnancy-associated plasma protein-A (PAPP-A) at 11 to 14 weeks of gestation is associated with a detection rate of 90% for a false-positive rate of 5%...

Discussions